<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36831264</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>12</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>TDP-43 Proteinopathy Specific Biomarker Development.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">597</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12040597</ELocationID><Abstract><AbstractText>TDP-43 is the primary or secondary pathological hallmark of neurodegenerative diseases, such as amyotrophic lateral sclerosis, half of frontotemporal dementia cases, and limbic age-related TDP-43 encephalopathy, which clinically resembles Alzheimer's dementia. In such diseases, a biomarker that can detect TDP-43 proteinopathy in life would help to stratify patients according to their definite diagnosis of pathology, rather than in clinical subgroups of uncertain pathology. For therapies developed to target pathological proteins that cause the disease a biomarker to detect and track the underlying pathology would greatly enhance such undertakings. This article reviews the latest developments and outlooks of deriving TDP-43-specific biomarkers from the pathophysiological processes involved in the development of TDP-43 proteinopathy and studies using biosamples from clinical entities associated with TDP-43 pathology to investigate biomarker candidates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cordts</LastName><ForeName>Isabell</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wachinger</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scialo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Quantitative Biomedicine, University of Zurich, 8057 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lingor</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9362-7096</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, DZNE, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polymenidou</LastName><ForeName>Magdalini</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1271-9445</Identifier><AffiliationInfo><Affiliation>Department of Quantitative Biomedicine, University of Zurich, 8057 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buratti</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1356-9074</Identifier><AffiliationInfo><Affiliation>Molecular Pathology, International Centre for Genetic Engineering and Biotechnology, 34149 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feneberg</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biofluid</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>1</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36831264</ArticleId><ArticleId IdType="pmc">PMC9954136</ArticleId><ArticleId IdType="doi">10.3390/cells12040597</ArticleId><ArticleId IdType="pii">cells12040597</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bott N.T., Radke A., Stephens M.L., Kramer J.H. Frontotemporal dementia: Diagnosis, deficits and management. Neurodegener Dis. Manag. 2014;4:439&#x2013;454. doi: 10.2217/nmt.14.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt.14.34</ArticleId><ArticleId IdType="pmc">PMC4824317</ArticleId><ArticleId IdType="pubmed">25531687</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellura E., Spataro R., Taiello A.C., La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin. Neurol. Neurosurg. 2012;114:550&#x2013;554. doi: 10.1016/j.clineuro.2011.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2011.11.026</ArticleId><ArticleId IdType="pubmed">22169158</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani G., Danti S., Nuti A., Di Fiorino M., Cammisuli D.M. Is that schizophrenia or frontotemporal dementia? Supporting clinicians in making the right diagnosis. Acta Neurol. Belg. 2020;120:799&#x2013;804. doi: 10.1007/s13760-020-01352-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-020-01352-z</ArticleId><ArticleId IdType="pubmed">32314269</ArticleId></ArticleIdList></Reference><Reference><Citation>Draper B., Cations M., White F., Trollor J., Loy C., Brodaty H., Sachdev P., Gonski P., Demirkol A., Cumming R.G., et al. Time to diagnosis in young-onset dementia and its determinants: The INSPIRED study. Int J. Geriatr. Psychiatry. 2016;31:1217&#x2013;1224. doi: 10.1002/gps.4430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.4430</ArticleId><ArticleId IdType="pubmed">26807846</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D., Morren J.A., Pioro E.P. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J. Neurol. Sci. 2020;417:117054. doi: 10.1016/j.jns.2020.117054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117054</ArticleId><ArticleId IdType="pubmed">32763509</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., McHutchison C., Postuma R.B., Boeve B.F., Petersen R., Ross C.A., Rosen H., Arias J.J., Fradette S., et al. Preventing amyotrophic lateral sclerosis: Insights from pre-symptomatic neurodegenerative diseases. Brain. 2022;145:27&#x2013;44. doi: 10.1093/brain/awab404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab404</ArticleId><ArticleId IdType="pmc">PMC8967095</ArticleId><ArticleId IdType="pubmed">34677606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Talbot K., McDermott C.J., Hardiman O., Shefner J.M., Al-Chalabi A., Huynh W., Cudkowicz M., Talman P., et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2021;17:104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Kiernan M.C., Leigh P.N., Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8:94&#x2013;109. doi: 10.1016/S1474-4422(08)70293-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70293-X</ArticleId><ArticleId IdType="pubmed">19081518</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Neumann M. Molecular neuropathology of frontotemporal dementia: Insights into disease mechanisms from postmortem studies. J. Neurochem. 2016;138((Suppl. 1)):54&#x2013;70. doi: 10.1111/jnc.13588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13588</ArticleId><ArticleId IdType="pubmed">27306735</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Neumann M., Bigio E.H., Cairns N.J., Alafuzoff I., Kril J., Kovacs G.G., Ghetti B., Halliday G., Holm I.E., et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: Consensus recommendations. Acta Neuropathol. 2009;117:15&#x2013;18. doi: 10.1007/s00401-008-0460-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0460-5</ArticleId><ArticleId IdType="pmc">PMC2710877</ArticleId><ArticleId IdType="pubmed">19015862</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C., Lin W.L., Ahmed Z., Personett D., Davies P., Duara R., Graff-Radford N.R., Hutton M.L., Dickson D.W. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann. Neurol. 2007;61:435&#x2013;445. doi: 10.1002/ana.21154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21154</ArticleId><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K.A., Whitwell J.L., Knopman D.S., Hu W.T., Stroh D.A., Baker M., Rademakers R., Boeve B.F., Parisi J.E., Smith G.E., et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology. 2008;70:1850&#x2013;1857. doi: 10.1212/01.wnl.0000304041.09418.b1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000304041.09418.b1</ArticleId><ArticleId IdType="pmc">PMC2779031</ArticleId><ArticleId IdType="pubmed">18401022</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P.T., Dickson D.W., Trojanowski J.Q., Jack C.R., Boyle P.A., Arfanakis K., Rademakers R., Alafuzoff I., Attems J., Brayne C., et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report. Brain. 2019 doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami I., Arai T., Hasegawa M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. 2019;138:751&#x2013;770. doi: 10.1007/s00401-019-02077-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02077-x</ArticleId><ArticleId IdType="pmc">PMC6800885</ArticleId><ArticleId IdType="pubmed">31555895</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan R.H., Ke Y.D., Ittner L.M., Halliday G.M. ALS/FTLD: Experimental models and reality. Acta Neuropathol. 2017;133:177&#x2013;196. doi: 10.1007/s00401-016-1666-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1666-6</ArticleId><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Toledo J.B., Robinson J.L., Irwin D.J., Grossman M., Suh E., Van Deerlin V.M., Wood E.M., Baek Y., et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Irwin D.J., Grossman M., Robinson J.L., Toledo J.B., Fang L., Van Deerlin V.M., Ludolph A.C., Lee V.M., et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) Acta Neuropathol. 2014;127:423&#x2013;439. doi: 10.1007/s00401-013-1238-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1238-y</ArticleId><ArticleId IdType="pmc">PMC3971993</ArticleId><ArticleId IdType="pubmed">24407427</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweingruber C., Hedlund E. The Cell Autonomous and Non-Cell Autonomous Aspects of Neuronal Vulnerability and Resilience in Amyotrophic Lateral Sclerosis. Biology. 2022;11 doi: 10.3390/biology11081191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology11081191</ArticleId><ArticleId IdType="pmc">PMC9405388</ArticleId><ArticleId IdType="pubmed">36009818</ArticleId></ArticleIdList></Reference><Reference><Citation>Susnjar U., Skrabar N., Brown A.L., Abbassi Y., Phatnani H., Consortium N.A., Cortese A., Cereda C., Bugiardini E., Cardani R., et al. Cell environment shapes TDP-43 function with implications in neuronal and muscle disease. Commun. Biol. 2022;5:314. doi: 10.1038/s42003-022-03253-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03253-8</ArticleId><ArticleId IdType="pmc">PMC8983780</ArticleId><ArticleId IdType="pubmed">35383280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Neumann M., Baborie A., Sampathu D.M., Du Plessis D., Jaros E., Perry R.H., Trojanowski J.Q., Mann D.M., Lee V.M. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113. doi: 10.1007/s00401-011-0845-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes L.R., Kalab P. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD. Neurotherapeutics. 2022;19:1061&#x2013;1084. doi: 10.1007/s13311-022-01260-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01260-5</ArticleId><ArticleId IdType="pmc">PMC9587158</ArticleId><ArticleId IdType="pubmed">35790708</ArticleId></ArticleIdList></Reference><Reference><Citation>Krecic A.M., Swanson M.S. hnRNP complexes: Composition, structure, and function. Curr. Opin. Cell Biol. 1999;11:363&#x2013;371. doi: 10.1016/S0955-0674(99)80051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0955-0674(99)80051-9</ArticleId><ArticleId IdType="pubmed">10395553</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Dork T., Zuccato E., Pagani F., Romano M., Baralle F.E. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20:1774&#x2013;1784. doi: 10.1093/emboj/20.7.1774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.7.1774</ArticleId><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Calvo A., Chio A., Colville S., Ellis C.M., Hardiman O., Heverin M., Howard R.S., Huisman M.H.B., Keren N., et al. Analysis of amyotrophic lateral sclerosis as a multistep process: A population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113. doi: 10.1016/S1474-4422(14)70219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky P.J., Daujotyte D., Tollervey J.R., Ule J., Stuani C., Buratti E., Baralle F.E., Damberger F.F., Allain F.H. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat. Struct Mol. Biol. 2013;20:1443&#x2013;1449. doi: 10.1038/nsmb.2698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2698</ArticleId><ArticleId IdType="pubmed">24240615</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T., Hock E.M., Ernst P., Foglieni C., Jambeau M., Gilhespy L.A.B., Laferriere F., Maniecka Z., Pluckthun A., Mittl P., et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat. Commun. 2017;8:45. doi: 10.1038/s41467-017-00062-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00062-0</ArticleId><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A., Conicella A.E., Schmidt H.B., Martin E.W., Rhoads S.N., Reeb A.N., Nourse A., Ramirez Montero D., Ryan V.H., Rohatgi R., et al. A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. EMBO J. 2018;37:7452. doi: 10.15252/embj.201797452.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797452</ArticleId><ArticleId IdType="pmc">PMC5830921</ArticleId><ArticleId IdType="pubmed">29438978</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ambrogio A., Buratti E., Stuani C., Guarnaccia C., Romano M., Ayala Y.M., Baralle F.E. Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res. 2009;37:4116&#x2013;4126. doi: 10.1093/nar/gkp342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkp342</ArticleId><ArticleId IdType="pmc">PMC2709582</ArticleId><ArticleId IdType="pubmed">19429692</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Brindisi A., Giombi M., Tisminetzky S., Ayala Y.M., Baralle F.E. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 2005;280:37572&#x2013;37584. doi: 10.1074/jbc.M505557200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505557200</ArticleId><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y.M., Pantano S., D&#x2019;Ambrogio A., Buratti E., Brindisi A., Marchetti C., Romano M., Baralle F.E. Human, Drosophila, and C.elegans TDP43: Nucleic acid binding properties and splicing regulatory function. J. Mol. Biol. 2005;348:575&#x2013;588. doi: 10.1016/j.jmb.2005.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.02.038</ArticleId><ArticleId IdType="pubmed">15826655</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartegni L., Maconi M., Morandi E., Cobianchi F., Riva S., Biamonti G. hnRNP A1 selectively interacts through its Gly-rich domain with different RNA-binding proteins. J. Mol. Biol. 1996;259:337&#x2013;348. doi: 10.1006/jmbi.1996.0324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1996.0324</ArticleId><ArticleId IdType="pubmed">8676373</ArticleId></ArticleIdList></Reference><Reference><Citation>Tziortzouda P., Van Den Bosch L., Hirth F. Triad of TDP43 control in neurodegeneration: Autoregulation, localization and aggregation. Nat. Rev. Neurosci. 2021;22:197&#x2013;208. doi: 10.1038/s41583-021-00431-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00431-1</ArticleId><ArticleId IdType="pubmed">33654312</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P., Sivakumar P., Humphrey J., Lo K., Ricketts T., Oliveira H., Brito-Armas J.M., Kalmar B., Ule A., Yu Y., et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37:8684. doi: 10.15252/embj.201798684.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798684</ArticleId><ArticleId IdType="pmc">PMC5983119</ArticleId><ArticleId IdType="pubmed">29764981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognesi B., Faure A.J., Seuma M., Schmiedel J.M., Tartaglia G.G., Lehner B. The mutational landscape of a prion-like domain. Nat. Commun. 2019;10:4162. doi: 10.1038/s41467-019-12101-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12101-z</ArticleId><ArticleId IdType="pmc">PMC6744496</ArticleId><ArticleId IdType="pubmed">31519910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann J.R., Donnelly C.J. RNA modulates physiological and neuropathological protein phase transitions. Neuron. 2021;109:2663&#x2013;2681. doi: 10.1016/j.neuron.2021.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.06.023</ArticleId><ArticleId IdType="pmc">PMC8434763</ArticleId><ArticleId IdType="pubmed">34297914</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompean M., Laurents D.V. Intrinsically Disordered Domains, Amyloids and Protein Liquid Phases: Evolving Concepts and Open Questions. Protein Pept Lett. 2017;24:281&#x2013;293. doi: 10.2174/0929866524666170206122106.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929866524666170206122106</ArticleId><ArticleId IdType="pubmed">28176659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L., Wei Y., Lu Y., Song J. ALS-Causing Mutations Significantly Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain of TDP-43. PLoS Biol. 2016;14:e1002338. doi: 10.1371/journal.pbio.1002338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002338</ArticleId><ArticleId IdType="pmc">PMC4703307</ArticleId><ArticleId IdType="pubmed">26735904</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.C., Sun E., Wancewicz E., Mazur C., et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011;14:459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiina Y., Arima K., Tabunoki H., Satoh J. TDP-43 dimerizes in human cells in culture. Cell Mol. Neurobiol. 2010;30:641&#x2013;652. doi: 10.1007/s10571-009-9489-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-009-9489-9</ArticleId><ArticleId IdType="pubmed">20043239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallegger M., Chakrabarti A.M., Lee F.C.Y., Lee B.L., Amalietti A.G., Odeh H.M., Copley K.E., Rubien J.D., Portz B., Kuret K., et al. TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. Cell. 2021;184:4680&#x2013;4696. doi: 10.1016/j.cell.2021.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.07.018</ArticleId><ArticleId IdType="pmc">PMC8445024</ArticleId><ArticleId IdType="pubmed">34380047</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin. Ther. Targets. 2018;22:279&#x2013;293. doi: 10.1080/14728222.2018.1439923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1439923</ArticleId><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Portz B., Lee B.L., Shorter J. FUS and TDP-43 Phases in Health and Disease. Trends Biochem. Sci. 2021;46:550&#x2013;563. doi: 10.1016/j.tibs.2020.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2020.12.005</ArticleId><ArticleId IdType="pmc">PMC8195841</ArticleId><ArticleId IdType="pubmed">33446423</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternburg E.L., Gruijs da Silva L.A., Dormann D. Post-translational modifications on RNA-binding proteins: Accelerators, brakes, or passengers in neurodegeneration? Trends Biochem. Sci. 2022;47:6&#x2013;22. doi: 10.1016/j.tibs.2021.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2021.07.004</ArticleId><ArticleId IdType="pubmed">34366183</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L.M., Kwong L.K., Lee E.B., Chen-Plotkin A., Swanson E., Unger T., Malunda J., Xu Y., Winton M.J., Trojanowski J.Q., et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 2011;121:726&#x2013;738. doi: 10.1172/JCI44867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44867</ArticleId><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y.M., De Conti L., Avendano-Vazquez S.E., Dhir A., Romano M., D&#x2019;Ambrogio A., Tollervey J., Ule J., Baralle M., Buratti E., et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30:277&#x2013;288. doi: 10.1038/emboj.2010.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.310</ArticleId><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y., Eid L., Parent M., Soucy G., Bareil C., Riku Y., Kawai K., Takagi S., Yoshida M., Katsuno M., et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016;139:3187&#x2013;3201. doi: 10.1093/brain/aww237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww237</ArticleId><ArticleId IdType="pmc">PMC5840881</ArticleId><ArticleId IdType="pubmed">27679482</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiler M.S., Strobel B., Freischmidt A., Helferich A.M., Kappel J., Brewer B.M., Li D., Thal D.R., Walther P., Ludolph A.C., et al. TDP-43 is intercellularly transmitted across axon terminals. J. Cell Biol. 2015;211:897&#x2013;911. doi: 10.1083/jcb.201504057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201504057</ArticleId><ArticleId IdType="pmc">PMC4657165</ArticleId><ArticleId IdType="pubmed">26598621</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P., Newcombe J., Troakes C., Simone R., Chen Y.R., Patani R., Sidle K. In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol. Dis. 2016;96:236&#x2013;247. doi: 10.1016/j.nbd.2016.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.08.007</ArticleId><ArticleId IdType="pmc">PMC5113659</ArticleId><ArticleId IdType="pubmed">27590623</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschini A., Baiardi S., Hughson A.G., McKenzie N., Moda F., Rossi M., Capellari S., Green A., Giaccone G., Caughey B., et al. High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions. Sci. Rep. 2017;7:10655. doi: 10.1038/s41598-017-10922-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-10922-w</ArticleId><ArticleId IdType="pmc">PMC5587608</ArticleId><ArticleId IdType="pubmed">28878311</ArticleId></ArticleIdList></Reference><Reference><Citation>Orru C.D., Groveman B.R., Hughson A.G., Zanusso G., Coulthart M.B., Caughey B. Rapid and sensitive RT-QuIC detection of human Creutzfeldt-Jakob disease using cerebrospinal fluid. mBio. 2015;6 doi: 10.1128/mBio.02451-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02451-14</ArticleId><ArticleId IdType="pmc">PMC4313917</ArticleId><ArticleId IdType="pubmed">25604790</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfoul G., McGuire L.I., Pal S., Ironside J.W., Neumann J., Christie S., Joachim C., Esiri M., Evetts S.G., Rolinski M., et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 2016;3:812&#x2013;818. doi: 10.1002/acn3.338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.338</ArticleId><ArticleId IdType="pmc">PMC5048391</ArticleId><ArticleId IdType="pubmed">27752516</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvadores N., Shahnawaz M., Scarpini E., Tagliavini F., Soto C. Detection of misfolded Abeta oligomers for sensitive biochemical diagnosis of Alzheimer&#x2019;s disease. Cell Rep. 2014;7:261&#x2013;268. doi: 10.1016/j.celrep.2014.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.02.031</ArticleId><ArticleId IdType="pubmed">24656814</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S., Xu Y., Restrepo C.R., Kwong L.K., Zhang B., Brown H.J., Lee E.B., Trojanowski J.Q., Lee V.M. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat. Commun. 2018;9:4220. doi: 10.1038/s41467-018-06548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06548-9</ArticleId><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Kaneko K., Watanabe S., Yamanaka K., Nukina N. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J. Biol. Chem. 2011;286:18664&#x2013;18672. doi: 10.1074/jbc.M111.231209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.231209</ArticleId><ArticleId IdType="pmc">PMC3099683</ArticleId><ArticleId IdType="pubmed">21454603</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009;284:20329&#x2013;20339. doi: 10.1074/jbc.M109.010264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Scialo C., Tran T.H., Salzano G., Novi G., Caponnetto C., Chio A., Calvo A., Canosa A., Moda F., Caroppo P., et al. TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Commun. 2020;2:fcaa142. doi: 10.1093/braincomms/fcaa142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa142</ArticleId><ArticleId IdType="pmc">PMC7566418</ArticleId><ArticleId IdType="pubmed">33094285</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer L., Gunther R., Koch J.C., Klebe S., Hagenacker T., Lingor P., Biesalski A.S., Hermann A., Nabers A., Gold R., et al. TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2021;8:271&#x2013;277. doi: 10.1002/acn3.51256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51256</ArticleId><ArticleId IdType="pmc">PMC7818221</ArticleId><ArticleId IdType="pubmed">33263951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Neumann M. Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathol. 2017;134:79&#x2013;96. doi: 10.1007/s00401-017-1716-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1716-8</ArticleId><ArticleId IdType="pubmed">28466142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.B., Porta S., Michael Baer G., Xu Y., Suh E., Kwong L.K., Elman L., Grossman M., Lee V.M., Irwin D.J., et al. Expansion of the classification of FTLD-TDP: Distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134:65&#x2013;78. doi: 10.1007/s00401-017-1679-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1679-9</ArticleId><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Ma L. Grey matter volume changes over the whole brain in amyotrophic lateral sclerosis: A voxel-wise meta-analysis of voxel based morphometry studies. Amyotroph Lateral Scler. 2010;11:549&#x2013;554. doi: 10.3109/17482968.2010.516265.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.516265</ArticleId><ArticleId IdType="pubmed">20929296</ArticleId></ArticleIdList></Reference><Reference><Citation>Broe M., Hodges J.R., Schofield E., Shepherd C.E., Kril J.J., Halliday G.M. Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology. 2003;60:1005&#x2013;1011. doi: 10.1212/01.WNL.0000052685.09194.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000052685.09194.39</ArticleId><ArticleId IdType="pubmed">12654969</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C.H., Grauffel C., Wu L.S., Kuo P.H., Doudeva L.G., Lim C., Shen C.K., Yuan H.S. Structural analysis of disease-related TDP-43 D169G mutation: Linking enhanced stability and caspase cleavage efficiency to protein accumulation. Sci. Rep. 2016;6:21581. doi: 10.1038/srep21581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep21581</ArticleId><ArticleId IdType="pmc">PMC4756693</ArticleId><ArticleId IdType="pubmed">26883171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer R.C., Chami A.A., de Assis D.R., Vourc&#x2019;h P., Andres C.R., Corcia P., Lanznaster D., Blasco H. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: A resolution in sight? Brain. 2019;142:1176&#x2013;1194. doi: 10.1093/brain/awz078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F., Obi T., Shishido T., Akatsu H., Murayama S., Saito Y., Yoshida M., Hasegawa M. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci. Rep. 2016;6:23281. doi: 10.1038/srep23281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23281</ArticleId><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F., Nonaka T., Suzuki T., Arai T., Dohmae N., Akiyama H., Hasegawa M. Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem. Biophys. Res. Commun. 2009;382:405&#x2013;409. doi: 10.1016/j.bbrc.2009.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.03.038</ArticleId><ArticleId IdType="pubmed">19285963</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T.G., Buratti E., Baralle F., Morita M., et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Cracco L., Doud E.H., Hallinan G.I., Garringer H.J., Jacobsen M.H., Richardson R.M., Buratti E., Vidal R., Ghetti B., Newell K.L. Distinguishing post-translational modifications in dominantly inherited frontotemporal dementias: FTLD-TDP Type A (GRN) vs Type B (C9orf72) Neuropathol. Appl. Neurobiol. 2022;48:e12836. doi: 10.1111/nan.12836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12836</ArticleId><ArticleId IdType="pmc">PMC9452479</ArticleId><ArticleId IdType="pubmed">35836354</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferriere F., Maniecka Z., Perez-Berlanga M., Hruska-Plochan M., Gilhespy L., Hock E.M., Wagner U., Afroz T., Boersema P.J., Barmettler G., et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat. Neurosci. 2019;22:65&#x2013;77. doi: 10.1038/s41593-018-0294-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0294-y</ArticleId><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E., Charles P.D., Finelli M.J., Scott C., Kessler B.M., Fischer R., Ansorge O., Gray E., Talbot K., Turner M.R. Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP. Brain Pathol. 2021;31:e12923. doi: 10.1111/bpa.12923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12923</ArticleId><ArticleId IdType="pmc">PMC8412074</ArticleId><ArticleId IdType="pubmed">33300249</ArticleId></ArticleIdList></Reference><Reference><Citation>Pobran T.D., Forgrave L.M., Zheng Y.Z., Lim J.G.K., Mackenzie I.R.A., DeMarco M.L. Detection and characterization of TDP-43 in human cells and tissues by multiple reaction monitoring mass spectrometry. Clin. Mass Spectrom. 2019;14 Pt B:66&#x2013;73. doi: 10.1016/j.clinms.2019.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinms.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC8669462</ArticleId><ArticleId IdType="pubmed">34917762</ArticleId></ArticleIdList></Reference><Reference><Citation>Pobran T.D., Yang D., Mackenzie I.R.A., DeMarco M.L. Aptamer-based enrichment of TDP-43 from human cells and tissues with quantification by HPLC-MS/MS. J. Neurosci. Methods. 2021;363:109344. doi: 10.1016/j.jneumeth.2021.109344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2021.109344</ArticleId><ArticleId IdType="pubmed">34469713</ArticleId></ArticleIdList></Reference><Reference><Citation>Donde A., Sun M., Ling J.P., Braunstein K.E., Pang B., Wen X., Cheng X., Chen L., Wong P.C. Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol. 2019;138:813&#x2013;826. doi: 10.1007/s00401-019-02042-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02042-8</ArticleId><ArticleId IdType="pmc">PMC6802294</ArticleId><ArticleId IdType="pubmed">31332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Highley J.R., Kirby J., Jansweijer J.A., Webb P.S., Hewamadduma C.A., Heath P.R., Higginbottom A., Raman R., Ferraiuolo L., Cooper-Knock J., et al. Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones. Neuropathol. Appl. Neurobiol. 2014;40:670&#x2013;685. doi: 10.1111/nan.12148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12148</ArticleId><ArticleId IdType="pubmed">24750229</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaber J., Talbot K. What is the role of TDP-43 in C9orf72-related amyotrophic lateral sclerosis and frontemporal dementia? Brain. 2016;139:3057&#x2013;3059. doi: 10.1093/brain/aww264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww264</ArticleId><ArticleId IdType="pubmed">27913405</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai S.C., Yoon S.J., Gardner R.C., Gendron T.F., Vargas J.N., Trujillo A., Pribadi M., Phillips J.J., Gaus S.E., Hixson J.D., et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016;139:3202&#x2013;3216. doi: 10.1093/brain/aww250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww250</ArticleId><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling J.P., Pletnikova O., Troncoso J.C., Wong P.C. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650&#x2013;655. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z., Lopez-Erauskin J., Baughn M.W., Zhang O., Drenner K., Sun Y., Freyermuth F., McMahon M.A., Beccari M.S., Artates J.W., et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A.L., Wilkins O.G., Keuss M.J., Hill S.E., Zanovello M., Lee W.C., Bampton A., Lee F.C.Y., Masino L., Qi Y.A., et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M., Humphrey J., Pickles S., Brown A.L., Hill S.E., Kachergus J.M., Shi J., Heckman M.G., Spiegel M.R., Cook C., et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J. Clin. Invest. 2020;130:6080&#x2013;6092. doi: 10.1172/JCI139741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI139741</ArticleId><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F., Anderton R.S., Mastaglia F.L., Flynn L.L., Winter S.J., James I., Bedlack R., Hodgetts S., Fletcher S., Wilton S.D., et al. Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype. Front. Aging Neurosci. 2021;13:658226. doi: 10.3389/fnagi.2021.658226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.658226</ArticleId><ArticleId IdType="pmc">PMC8033025</ArticleId><ArticleId IdType="pubmed">33841129</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim J.R., Williams L.A., Limone F., Guerra San Juan I., Davis-Dusenbery B.N., Mordes D.A., Burberry A., Steinbaugh M.J., Gamage K.K., Kirchner R., et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X.R., Prudencio M., Koike Y., Vatsavayai S.C., Kim G., Harbinski F., Briner A., Rodriguez C.M., Guo C., Akiyama T., et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603:124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin I., Rosenmund C., Sudhof T.C., Brose N. Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. Nature. 1999;400:457&#x2013;461. doi: 10.1038/22768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/22768</ArticleId><ArticleId IdType="pubmed">10440375</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng L., Kaeser P.S., Xu W., Sudhof T.C. RIM proteins activate vesicle priming by reversing autoinhibitory homodimerization of Munc13. Neuron. 2011;69:317&#x2013;331. doi: 10.1016/j.neuron.2011.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.01.005</ArticleId><ArticleId IdType="pmc">PMC3063404</ArticleId><ArticleId IdType="pubmed">21262469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipstein N., Verhoeven-Duif N.M., Michelassi F.E., Calloway N., van Hasselt P.M., Pienkowska K., van Haaften G., van Haelst M.M., van Empelen R., Cuppen I., et al. Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder. J. Clin. Invest. 2017;127:1005&#x2013;1018. doi: 10.1172/JCI90259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90259</ArticleId><ArticleId IdType="pmc">PMC5330740</ArticleId><ArticleId IdType="pubmed">28192369</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H.H.G., Westeneng H.J., van der Burgh H.K., van Es M.A., Bakker L.A., van Veenhuijzen K., van Eijk K.R., van Eijk R.P.A., Veldink J.H., van den Berg L.H. The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis. Ann. Neurol. 2020;88:796&#x2013;806. doi: 10.1002/ana.25841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25841</ArticleId><ArticleId IdType="pmc">PMC7540607</ArticleId><ArticleId IdType="pubmed">32627229</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra F.P., Van Deerlin V.M., van Swieten J.C., Al-Chalabi A., Ludolph A.C., Weishaupt J.H., Hardiman O., Landers J.E., Brown R.H., Jr., van Es M.A., et al. C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genome-wide meta-analysis. Ann. Neurol. 2014;76:120&#x2013;133. doi: 10.1002/ana.24198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24198</ArticleId><ArticleId IdType="pmc">PMC4137231</ArticleId><ArticleId IdType="pubmed">24931836</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra F.P., van Vught P.W., van Rheenen W., Koppers M., Pasterkamp R.J., van Es M.A., Schelhaas H.J., de Visser M., Robberecht W., Van Damme P., et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol. Aging. 2012;33:630-e3. doi: 10.1016/j.neurobiolaging.2011.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.029</ArticleId><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Veldink J.H., Saris C.G., Blauw H.M., van Vught P.W., Birve A., Lemmens R., Schelhaas H.J., Groen E.J., Huisman M.H., et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet. 2009;41:1083&#x2013;1087. doi: 10.1038/ng.442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.442</ArticleId><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hruska-Plochan M., Betz K.M., Ronchi S., Wiersma V.I., Maniecka Z., Hock E.M., Laferriere F., Sahadevan S., Hoop V., Delvendahl I., et al. Human neural networks with sparse TDP-43 pathology reveal NPTX2 misregulation in ALS/FTLD. bioRxiv. 2021;9:12. doi: 10.1101/2021.12.08.471089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.08.471089</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey J.R., Curk T., Rogelj B., Briese M., Cereda M., Kayikci M., Konig J., Hortobagyi T., Nishimura A.L., Zupunski V., et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 2011;14:452&#x2013;458. doi: 10.1038/nn.2778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2778</ArticleId><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende E.L., Xiao M., Xu D., Poos J.M., Panman J.L., Jiskoot L.C., Meeter L.H., Dopper E.G., Papma J.M., Heller C., et al. Neuronal pentraxin 2: A synapse-derived CSF biomarker in genetic frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. 2020;91:612&#x2013;621. doi: 10.1136/jnnp-2019-322493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322493</ArticleId><ArticleId IdType="pmc">PMC7279197</ArticleId><ArticleId IdType="pubmed">32273328</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Green C., Altschuler G., Wei W., Bury J.J., Heath P.R., Wyles M., Gelsthorpe C., Highley J.R., Lorente-Pons A., et al. A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2017;5:23. doi: 10.1186/s40478-017-0424-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0424-x</ArticleId><ArticleId IdType="pmc">PMC5353945</ArticleId><ArticleId IdType="pubmed">28302159</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P., Weydt P., Thal D.R., Weishaupt J.H., Ludolph A.C., Otto M. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020;139:119&#x2013;134. doi: 10.1007/s00401-019-02093-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02093-x</ArticleId><ArticleId IdType="pubmed">31701227</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian Y., Zheng R., Bayer F.P., Wong C., Chang Y.C., Meng C., Zolg D.P., Reinecke M., Zecha J., Wiechmann S., et al. Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS/MS. Nat. Commun. 2020;11:157. doi: 10.1038/s41467-019-13973-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13973-x</ArticleId><ArticleId IdType="pmc">PMC6952431</ArticleId><ArticleId IdType="pubmed">31919466</ArticleId></ArticleIdList></Reference><Reference><Citation>Heywood W.E., Galimberti D., Bliss E., Sirka E., Paterson R.W., Magdalinou N.K., Carecchio M., Reid E., Heslegrave A., Fenoglio C., et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol. Neurodegener. 2015;10:64. doi: 10.1186/s13024-015-0059-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0059-y</ArticleId><ArticleId IdType="pmc">PMC4666172</ArticleId><ArticleId IdType="pubmed">26627638</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S.A., Itaman S., Khalid-Janney C.M., Sherard J.A., Dowell J.A., Cairns N.J., Gitcho M.A. TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neurosci. Lett. 2018;678:8&#x2013;15. doi: 10.1016/j.neulet.2018.04.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.04.053</ArticleId><ArticleId IdType="pmc">PMC5975202</ArticleId><ArticleId IdType="pubmed">29715546</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh M.E., Dammer E.B., Dai J., Duong D.M., Lah J.J., Levey A.I., Gearing M., Glass J.D., Seyfried N.T. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol. Med. 2018;10:48&#x2013;62. doi: 10.15252/emmm.201708202.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201708202</ArticleId><ArticleId IdType="pmc">PMC5760858</ArticleId><ArticleId IdType="pubmed">29191947</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A.R., Gregory J.M., Dando O., Carter R.N., Burr K., Nanda J., Story D., McDade K., Smith C., Morton N.M., et al. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol. 2021;141:257&#x2013;279. doi: 10.1007/s00401-020-02252-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02252-5</ArticleId><ArticleId IdType="pmc">PMC7847443</ArticleId><ArticleId IdType="pubmed">33398403</ArticleId></ArticleIdList></Reference><Reference><Citation>Paron F., Barattucci S., Cappelli S., Romano M., Berlingieri C., Stuani C., Laurents D., Mompean M., Buratti E. Unraveling the toxic effects mediated by the neurodegenerative disease-associated S375G mutation of TDP-43 and its S375E phosphomimetic variant. J. Biol. Chem. 2022;298:102252. doi: 10.1016/j.jbc.2022.102252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.102252</ArticleId><ArticleId IdType="pmc">PMC9364110</ArticleId><ArticleId IdType="pubmed">35835219</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.H., Davidson S., Harapas C.R., Hilton J.B., Mlodzianoski M.J., Laohamonthonkul P., Louis C., Low R.R.J., Moecking J., De Nardo D., et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020;183:636&#x2013;649.e618. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucini C.B., Braun R.J. Mitochondrion-Dependent Cell Death in TDP-43 Proteinopathies. Biomedicines. 2021;9:376. doi: 10.3390/biomedicines9040376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9040376</ArticleId><ArticleId IdType="pmc">PMC8066287</ArticleId><ArticleId IdType="pubmed">33918437</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., Muller K., Marroquin N., Nordin F., Hubers A., Weydt P., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., Sieverding K., Bruno C., Luningschror P., Buck E., Mungwa S., Fischer L., Brockmann S.J., Ulmer J., Bliederhauser C., et al. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J. Exp. Med. 2019;216:267&#x2013;278. doi: 10.1084/jem.20180729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180729</ArticleId><ArticleId IdType="pmc">PMC6363427</ArticleId><ArticleId IdType="pubmed">30635357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan-Jones W.R., Cope T.E., Jones P.S., Kaalund S.S., Passamonti L., Allinson K., Green O., Hong Y.T., Fryer T.D., Arnold R., et al. Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. Brain. 2020;143:1010&#x2013;1026. doi: 10.1093/brain/awaa033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa033</ArticleId><ArticleId IdType="pmc">PMC7089669</ArticleId><ArticleId IdType="pubmed">32179883</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Verde F., Fang L., Feneberg E., Oeckl P., Roeber S., Anderl-Straub S., Danek A., Diehl-Schmid J., Fassbender K., et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J. Neurol. Neurosurg. Psychiatry. 2018;89:239&#x2013;247. doi: 10.1136/jnnp-2017-317138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Thezenas M.L., Charles P.D., Evetts S., Hu M.T., Talbot K., Fischer R., Kessler B.M., Turner M.R. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann. Neurol. 2018;83:258&#x2013;268. doi: 10.1002/ana.25143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25143</ArticleId><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Dedeene L., Goossens J., Claeys K.G., Van Den Bosch L., Tournoy J., Van Damme P., Poesen K. Inflammatory markers in cerebrospinal fluid: Independent prognostic biomarkers in amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry. 2019;90:1338&#x2013;1346. doi: 10.1136/jnnp-2018-319586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S., Steinacker P., Polischi B., Mammana A., Bartoletti-Stella A., Oeckl P., Baiardi S., Zenesini C., Huss A., Cortelli P., et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res. Ther. 2019;12:2. doi: 10.1186/s13195-019-0562-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0562-4</ArticleId><ArticleId IdType="pmc">PMC6937795</ArticleId><ArticleId IdType="pubmed">31892365</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P., Weydt P., Steinacker P., Anderl-Straub S., Nordin F., Volk A.E., Diehl-Schmid J., Andersen P.M., Kornhuber J., Danek A., et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J. Neurol. Neurosurg. Psychiatry. 2019;90:4&#x2013;10. doi: 10.1136/jnnp-2018-318868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318868</ArticleId><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Bampton A., Raciborska D., Talbot K., Turner M.R. CSF chitinase proteins in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:1215&#x2013;1220. doi: 10.1136/jnnp-2019-320442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Illan-Gala I., Alcolea D., Montal V., Dols-Icardo O., Munoz L., de Luna N., Turon-Sans J., Cortes-Vicente E., Sanchez-Saudinos M.B., Subirana A., et al. CSF sAPPbeta, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 2018;91:e1619&#x2013;e1628. doi: 10.1212/WNL.0000000000006383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006383</ArticleId><ArticleId IdType="pubmed">30291183</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.C., Polymenidou M., Cleveland D.W. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer E.M.J., Orie V.K., Williams T., Baker M.R., De Oliveira H.M., Polvikoski T., Silsby M., Menon P., van den Bos M., Halliday G.M., et al. TDP-43 proteinopathies: A new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry. 2020 doi: 10.1136/jnnp-2020-322983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo M., Zetterberg H., Gandy S., Onyike C.U., Oliveira F., Udeh-Momoh C., Lleo A., Teunissen C.E., Pijnenburg Y. New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement. 2022;18:2292&#x2013;22307. doi: 10.1002/alz.12643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12643</ArticleId><ArticleId IdType="pmc">PMC9790674</ArticleId><ArticleId IdType="pubmed">35235699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Mazzini L., D&#x2019;Alfonso S., Corrado L., Canosa A., Moglia C., Manera U., Bersano E., Brunetti M., Barberis M., et al. The multistep hypothesis of ALS revisited: The role of genetic mutations. Neurology. 2018;91:e635&#x2013;e642. doi: 10.1212/WNL.0000000000005996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L., Grassano M., Pozzi S., Luotti S., Sammali E., Migazzi A., Basso M., Spagnolli G., Biasini E., Micotti E., et al. Defective cyclophilin A induces TDP-43 proteinopathy: Implications for amyotrophic lateral sclerosis and frontotemporal dementia. Brain. 2021;144:3710&#x2013;3726. doi: 10.1093/brain/awab333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab333</ArticleId><ArticleId IdType="pmc">PMC8719849</ArticleId><ArticleId IdType="pubmed">34972208</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Pozzi S., Pignataro M., Lauranzano E., Spano G., Garbelli S., Mantovani S., Marinou K., Papetti L., Monteforte M., et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS ONE. 2011;6:e25545. doi: 10.1371/journal.pone.0025545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025545</ArticleId><ArticleId IdType="pmc">PMC3187793</ArticleId><ArticleId IdType="pubmed">21998667</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L., Callegaro S., Corbelli A., Fiordaliso F., Ferrara D., Brunelli L., Sestito G., Pastorelli R., Bianchi E., Cretich M., et al. Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. Mol. Neurodegener. 2021;16:52. doi: 10.1186/s13024-021-00470-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00470-3</ArticleId><ArticleId IdType="pmc">PMC8353748</ArticleId><ArticleId IdType="pubmed">34376243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C., Oeckl P., Weishaupt J.H., Volk A.E., Diehl-Schmid J., Schroeter M.L., Lauer M., Kornhuber J., Levin J., Fassbender K., et al. Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Mol. Med. 2017;9:859&#x2013;868. doi: 10.15252/emmm.201607486.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607486</ArticleId><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Genge A., Shaw P.J., Sobue G., Bucelli R.C., Chio A., Van Damme P., Ludolph A.C., Glass J.D., et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer L., Srinivasan D., Chun S., Lacomis D., Jaffa M., Fagan A., Holtzman D.M., Wancewicz E., Bennett C.F., Bowser R., et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70:201&#x2013;207. doi: 10.1001/jamaneurol.2013.593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.593</ArticleId><ArticleId IdType="pmc">PMC3812918</ArticleId><ArticleId IdType="pubmed">23147550</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitan C., Hornstein E. Vulnerability of microRNA biogenesis in FTD-ALS. Brain Res. 2016;1647:105&#x2013;111. doi: 10.1016/j.brainres.2015.12.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2015.12.063</ArticleId><ArticleId IdType="pubmed">26778173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gascon E., Gao F.B. The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders. J. Neurogenet. 2014;28:30&#x2013;40. doi: 10.3109/01677063.2013.876021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01677063.2013.876021</ArticleId><ArticleId IdType="pmc">PMC4199862</ArticleId><ArticleId IdType="pubmed">24506814</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Muller K., Zondler L., Weydt P., Volk A.E., Bozic A.L., Walter M., Bonin M., Mayer B., von Arnim C.A., et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 2014;137:2938&#x2013;2950. doi: 10.1093/brain/awu249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu249</ArticleId><ArticleId IdType="pubmed">25193138</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y., Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl. Acad. Sci. USA. 2012;109:3347&#x2013;3352. doi: 10.1073/pnas.1112427109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1112427109</ArticleId><ArticleId IdType="pmc">PMC3295278</ArticleId><ArticleId IdType="pubmed">22323604</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., De Conti L., Stuani C., Romano M., Baralle M., Baralle F. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J. 2010;277:2268&#x2013;2281. doi: 10.1111/j.1742-4658.2010.07643.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2010.07643.x</ArticleId><ArticleId IdType="pubmed">20423455</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Muller K., Ludolph A.C., Weishaupt J.H. Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2013;1:42. doi: 10.1186/2051-5960-1-42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-1-42</ArticleId><ArticleId IdType="pmc">PMC3893596</ArticleId><ArticleId IdType="pubmed">24252274</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinar A., Koritnik B., Glavac D., Ravnik-Glavac M. Circular RNAs as Potential Blood Biomarkers in Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2019;56:8052&#x2013;8062. doi: 10.1007/s12035-019-1627-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1627-x</ArticleId><ArticleId IdType="pmc">PMC6834740</ArticleId><ArticleId IdType="pubmed">31175544</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi S., Zucca S., Pandini C., Diamanti L., Bordoni M., Sproviero D., Arigoni M., Olivero M., Pansarasa O., Ceroni M., et al. Long non-coding and coding RNAs characterization in Peripheral Blood Mononuclear Cells and Spinal Cord from Amyotrophic Lateral Sclerosis patients. Sci. Rep. 2018;8:2378. doi: 10.1038/s41598-018-20679-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20679-5</ArticleId><ArticleId IdType="pmc">PMC5799454</ArticleId><ArticleId IdType="pubmed">29402919</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Wang Z., Liu L., Yang Z., Liu S., Ma Z., Liu Y., Ma Y., Zhang L., Zhang X., et al. LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. Proc. Natl. Acad. Sci. USA. 2020;117:23695&#x2013;23706. doi: 10.1073/pnas.2003932117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2003932117</ArticleId><ArticleId IdType="pmc">PMC7519350</ArticleId><ArticleId IdType="pubmed">32907941</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsukawa K., Kukharsky M.S., Park S.K., Park S., Watanabe N., Iwatsubo T., Hashimoto T., Liebman S.W., Shelkovnikova T.A. Long non-coding RNA NEAT1_1 ameliorates TDP-43 toxicity in in vivo models of TDP-43 proteinopathy. RNA Biol. 2021;18:1546&#x2013;1554. doi: 10.1080/15476286.2020.1860580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2020.1860580</ArticleId><ArticleId IdType="pmc">PMC8583295</ArticleId><ArticleId IdType="pubmed">33427561</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen C.E., Elias N., Koel-Simmelink M.J., Durieux-Lu S., Malekzadeh A., Pham T.V., Piersma S.R., Beccari T., Meeter L.H., Dopper E.G., et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement. (Amst) 2016;2:86&#x2013;94. doi: 10.1016/j.dadm.2015.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2015.12.004</ArticleId><ArticleId IdType="pmc">PMC4879654</ArticleId><ArticleId IdType="pubmed">27239539</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H., Rohrer J.D., Pijnenburg Y.A., Fox N.C., van Swieten J.C. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review. J. Neurol. Neurosurg. Psychiatry. 2011;82:476&#x2013;486. doi: 10.1136/jnnp.2010.212225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.212225</ArticleId><ArticleId IdType="pubmed">20971753</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R., Brophy C., Hickling M., Neve J., Furger A. Alternative cleavage and polyadenylation of genes associated with protein turnover and mitochondrial function are deregulated in Parkinson&#x2019;s, Alzheimer&#x2019;s and ALS disease. BMC Med. Genomics. 2019;12:60. doi: 10.1186/s12920-019-0509-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-019-0509-4</ArticleId><ArticleId IdType="pmc">PMC6507032</ArticleId><ArticleId IdType="pubmed">31072331</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama A., Sugai A., Kato T., Ishihara T., Shiga A., Toyoshima Y., Koyama M., Konno T., Hirokawa S., Yokoseki A., et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 2016;44:5820&#x2013;5836. doi: 10.1093/nar/gkw499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw499</ArticleId><ArticleId IdType="pmc">PMC4937342</ArticleId><ArticleId IdType="pubmed">27257061</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaka H., Wang Y.L., Takada K., Takizawa S., Setsuie R., Li H., Sato Y., Nishikawa K., Sun Y.J., Sakurai M., et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 2003;12:1945&#x2013;1958. doi: 10.1093/hmg/ddg211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg211</ArticleId><ArticleId IdType="pubmed">12913066</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell N.E., McAlary L., Lum J.S., Chisholm C.G., Warraich S.T., Blair I.P., Vine K.L., Saunders D.N., Yerbury J.J. Ubiquitin Homeostasis Is Disrupted in TDP-43 and FUS Cell Models of ALS. iScience. 2020;23:101700. doi: 10.1016/j.isci.2020.101700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101700</ArticleId><ArticleId IdType="pmc">PMC7644588</ArticleId><ArticleId IdType="pubmed">33196025</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Feneberg E., Weishaupt J., Brettschneider J., Tumani H., Andersen P.M., von Arnim C.A., Bohm S., Kassubek J., Kubisch C., et al. Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry. 2016;87:12&#x2013;20. doi: 10.1136/jnnp-2015-311387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Chew J., Stankowski J.N., Hayes L.R., Zhang Y.J., Prudencio M., Carlomagno Y., Daughrity L.M., Jansen-West K., Perkerson E.A., et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9 doi: 10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C., Preische O., Deuschle C., Roeben B., Apel A., Barro C., Maia L., Maetzler W., Kuhle J., Synofzik M. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J. Neurol. Neurosurg. Psychiatry. 2016;87:1270&#x2013;1272. doi: 10.1136/jnnp-2015-312972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-312972</ArticleId><ArticleId IdType="pubmed">27188986</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende E.L., Meeter L.H., Poos J.M., Panman J.L., Jiskoot L.C., Dopper E.G.P., Papma J.M., de Jong F.J., Verberk I.M.W., Teunissen C., et al. Serum neurofilament light chain in genetic frontotemporal dementia: A longitudinal, multicentre cohort study. Lancet Neurol. 2019;18:1103&#x2013;1111. doi: 10.1016/S1474-4422(19)30354-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30354-0</ArticleId><ArticleId IdType="pubmed">31701893</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Spinola A., Lima M., Leitao M.J., Duraes J., Tabuas-Pereira M., Almeida M.R., Santana I., Baldeiras I. Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia. Eur. J. Neurol. 2022;29:36&#x2013;46. doi: 10.1111/ene.15058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15058</ArticleId><ArticleId IdType="pubmed">34375485</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaby C., Alcolea D., Carmona-Iragui M., Illan-Gala I., Morenas-Rodriguez E., Barroeta I., Altuna M., Estelles T., Santos-Santos M., Turon-Sans J., et al. Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci. Rep. 2020;10:9161. doi: 10.1038/s41598-020-66090-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-66090-x</ArticleId><ArticleId IdType="pmc">PMC7280194</ArticleId><ArticleId IdType="pubmed">32514050</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S., Mometto N., Bartoletti-Stella A., Polischi B., Oppi F., Poda R., Stanzani-Maserati M., Cortelli P., Liguori R., Capellari S., et al. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. J. Alzheimers Dis. 2018;66:551&#x2013;563. doi: 10.3233/JAD-180409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180409</ArticleId><ArticleId IdType="pubmed">30320576</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M., Kleinberger G., Araque Caballero M.A., Brendel M., Rominger A., Alcolea D., Fortea J., Lleo A., Blesa R., Gispert J.D., et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer&#x2019;s disease and associate with neuronal injury markers. EMBO Mol. Med. 2016;8:466&#x2013;476. doi: 10.15252/emmm.201506123.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201506123</ArticleId><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott I.O.C., Nicholas J.M., Heslegrave A., Heller C., Foiani M.S., Dick K.M., Russell L.L., Paterson R.W., Keshavan A., Fox N.C., et al. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Alzheimers Res. Ther. 2018;10:79. doi: 10.1186/s13195-018-0405-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0405-8</ArticleId><ArticleId IdType="pmc">PMC6094471</ArticleId><ArticleId IdType="pubmed">30111356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenik B., Sephton C.F., Kutluk Cenik B., Herz J., Yu G. Progranulin: A proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J. Biol. Chem. 2012;287:32298&#x2013;32306. doi: 10.1074/jbc.R112.399170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R112.399170</ArticleId><ArticleId IdType="pmc">PMC3463300</ArticleId><ArticleId IdType="pubmed">22859297</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellami L., Rucheton B., Ben Younes I., Camuzat A., Saracino D., Rinaldi D., Epelbaum S., Azuar C., Levy R., Auriacombe S., et al. Plasma progranulin levels for frontotemporal dementia in clinical practice: A 10-year French experience. Neurobiol. Aging. 2020;91:167-e1. doi: 10.1016/j.neurobiolaging.2020.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.02.014</ArticleId><ArticleId IdType="pubmed">32171590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortvelyessy P., Heinze H.J., Prudlo J., Bittner D. CSF Biomarkers of Neurodegeneration in Progressive Non-fluent Aphasia and Other Forms of Frontotemporal Dementia: Clues for Pathomechanisms? Front. Neurol. 2018;9:504. doi: 10.3389/fneur.2018.00504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00504</ArticleId><ArticleId IdType="pmc">PMC6036143</ArticleId><ArticleId IdType="pubmed">30013506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper Y.A., Nachun D., Dokuru D., Yang Z., Karydas A.M., Serrero G., Yue B., Alzheimer&#x2019;s Disease Neuroimaging I., Boxer A.L., Miller B.L., et al. Progranulin levels in blood in Alzheimer&#x2019;s disease and mild cognitive impairment. Ann. Clin. Transl. Neurol. 2018;5:616&#x2013;629. doi: 10.1002/acn3.560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.560</ArticleId><ArticleId IdType="pmc">PMC5945969</ArticleId><ArticleId IdType="pubmed">29761124</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E., Olsson B., Hoglund K., Cullen N.C., Kvartsberg H., Andreasson U., Zetterberg H., Sandelius A., Shaw L.M., Lee V.M.Y., et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: Relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136:363&#x2013;376. doi: 10.1007/s00401-018-1851-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1851-x</ArticleId><ArticleId IdType="pmc">PMC6096740</ArticleId><ArticleId IdType="pubmed">29700597</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S., Hertze J., Zetterberg H., Landqvist Waldo M., Santillo A., Blennow K., Hansson O. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer&#x2019;s disease. Ann. Clin. Transl. Neurol. 2016;3:12&#x2013;20. doi: 10.1002/acn3.266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.266</ArticleId><ArticleId IdType="pmc">PMC4704480</ArticleId><ArticleId IdType="pubmed">26783546</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke M.T.M., Brinkmalm A., Foiani M.S., Woollacott I.O.C., Heller C., Heslegrave A., Keshavan A., Fox N.C., Schott J.M., Warren J.D., et al. CSF synaptic protein concentrations are raised in those with atypical Alzheimer&#x2019;s disease but not frontotemporal dementia. Alzheimers Res. Ther. 2019;11:105. doi: 10.1186/s13195-019-0564-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0564-2</ArticleId><ArticleId IdType="pmc">PMC6918699</ArticleId><ArticleId IdType="pubmed">31847891</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm A., Brinkmalm G., Honer W.G., Frolich L., Hausner L., Minthon L., Hansson O., Wallin A., Zetterberg H., Blennow K., et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer&#x2019;s disease. Mol. Neurodegener. 2014;9:53. doi: 10.1186/1750-1326-9-53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-53</ArticleId><ArticleId IdType="pmc">PMC4253625</ArticleId><ArticleId IdType="pubmed">25418885</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P., Westman-Brinkmalm A., Nilsson C.L., Lindbjer M., Paulson L., Andreasen N., Sjogren M., Blennow K. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport. 2002;13:611&#x2013;615. doi: 10.1097/00001756-200204160-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200204160-00015</ArticleId><ArticleId IdType="pubmed">11973456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruetschi U., Zetterberg H., Podust V.N., Gottfries J., Li S., Hviid Simonsen A., McGuire J., Karlsson M., Rymo L., Davies H., et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp. Neurol. 2005;196:273&#x2013;281. doi: 10.1016/j.expneurol.2005.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.08.002</ArticleId><ArticleId IdType="pubmed">16154129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gloeckner S.F., Meyne F., Wagner F., Heinemann U., Krasnianski A., Meissner B., Zerr I. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J. Alzheimers Dis. 2008;14:17&#x2013;25. doi: 10.3233/JAD-2008-14102.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2008-14102</ArticleId><ArticleId IdType="pubmed">18525124</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Wang H., Li C., Niu H., Luo S., Guo X. Association between clusterin concentration and dementia: A systematic review and meta-analysis. Metab Brain Dis. 2019;34:129&#x2013;140. doi: 10.1007/s11011-018-0325-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-018-0325-0</ArticleId><ArticleId IdType="pubmed">30291488</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C., Hopfner F., Katsikoudi A., Hein R., Catli C., Evetts S., Huang Y., Wang H., Ryder J.W., Kuhlenbaeumer G., et al. Serum neuronal exosomes predict and differentiate Parkinson&#x2019;s disease from atypical parkinsonism. J. Neurol. Neurosurg. Psychiatry. 2020;91:720&#x2013;729. doi: 10.1136/jnnp-2019-322588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322588</ArticleId><ArticleId IdType="pmc">PMC7361010</ArticleId><ArticleId IdType="pubmed">32273329</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty L., Henderson R.D., McCombe P.A., Lee A. Levels of clusterin, CD5L, ficolin-3, and gelsolin in ALS patients and controls. Amyotroph Lateral Scler Front. Degener. 2020;21:631&#x2013;634. doi: 10.1080/21678421.2020.1779303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779303</ArticleId><ArticleId IdType="pubmed">32558599</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter L.H.H., Vijverberg E.G., Del Campo M., Rozemuller A.J.M., Donker Kaat L., de Jong F.J., van der Flier W.M., Teunissen C.E., van Swieten J.C., Pijnenburg Y.A.L. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90:e1231&#x2013;e1239. doi: 10.1212/WNL.0000000000005261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005261</ArticleId><ArticleId IdType="pmc">PMC5890612</ArticleId><ArticleId IdType="pubmed">29514947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijnenburg Y.A., Verwey N.A., van der Flier W.M., Scheltens P., Teunissen C.E. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement. (Amst) 2015;1:505&#x2013;512. doi: 10.1016/j.dadm.2015.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2015.11.001</ArticleId><ArticleId IdType="pmc">PMC4879490</ArticleId><ArticleId IdType="pubmed">27239528</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila A., Kuvaja M., Hartikainen P., Siloaho M., Helisalmi S., Moilanen V., Kiviharju A., Jansson L., Tienari P.J., Remes A.M., et al. Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion. Dement. Geriatr. Cogn. Dis. Extra. 2016;6:142&#x2013;149. doi: 10.1159/000444788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000444788</ArticleId><ArticleId IdType="pmc">PMC4868946</ArticleId><ArticleId IdType="pubmed">27195002</ArticleId></ArticleIdList></Reference><Reference><Citation>Noto Y., Shibuya K., Sato Y., Kanai K., Misawa S., Sawai S., Mori M., Uchiyama T., Isose S., Nasu S., et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: Specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler. 2011;12:140&#x2013;143. doi: 10.3109/17482968.2010.541263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.541263</ArticleId><ArticleId IdType="pubmed">21126161</ArticleId></ArticleIdList></Reference><Reference><Citation>Katisko K., Huber N., Kokkola T., Hartikainen P., Kruger J., Heikkinen A.L., Paananen V., Leinonen V., Korhonen V.E., Helisalmi S., et al. Serum total TDP-43 levels are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant motoneuron disease phenotype. Alzheimers Res. Ther. 2022;14:151. doi: 10.1186/s13195-022-01091-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-022-01091-8</ArticleId><ArticleId IdType="pmc">PMC9552448</ArticleId><ArticleId IdType="pubmed">36217158</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Hendrich C., Sperfeld A.D., Jesse S., von Arnim C.A., Lehnert S., Pabst A., Uttner I., Tumani H., Lee V.M., et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol. 2008;65:1481&#x2013;1487. doi: 10.1001/archneur.65.11.1481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.11.1481</ArticleId><ArticleId IdType="pmc">PMC2690860</ArticleId><ArticleId IdType="pubmed">19001167</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M., Dols-Icardo O., Llado A., Sanchez-Valle R., Hernandez I., Amer G., Anton-Aguirre S., Alcolea D., Fortea J., Ferrer I., et al. Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. J. Neurol. Neurosurg. Psychiatry. 2014;85:684&#x2013;691. doi: 10.1136/jnnp-2013-305972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305972</ArticleId><ArticleId IdType="pubmed">24309270</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulds P., McAuley E., Gibbons L., Davidson Y., Pickering-Brown S.M., Neary D., Snowden J.S., Allsop D., Mann D.M. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Acta Neuropathol. 2008;116:141&#x2013;146. doi: 10.1007/s00401-008-0389-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0389-8</ArticleId><ArticleId IdType="pmc">PMC2464623</ArticleId><ArticleId IdType="pubmed">18506455</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulds P.G., Davidson Y., Mishra M., Hobson D.J., Humphreys K.M., Taylor M., Johnson N., Weintraub S., Akiyama H., Arai T., et al. Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol. 2009;118:647&#x2013;658. doi: 10.1007/s00401-009-0594-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0594-0</ArticleId><ArticleId IdType="pmc">PMC2809136</ArticleId><ArticleId IdType="pubmed">19823856</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M., Teunissen C.E., Otto M., Piehl F., Sormani M.P., Gattringer T., Barro C., Kappos L., Comabella M., Fazekas F., et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 2018;14:577&#x2013;589. doi: 10.1038/s41582-018-0058-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F., Steinacker P., Weishaupt J.H., Kassubek J., Oeckl P., Halbgebauer S., Tumani H., von Arnim C.A.F., Dorst J., Feneberg E., et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:157&#x2013;164. doi: 10.1136/jnnp-2018-318704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Group C.O.N.S., Daughrity L.M., Heckman M.G., Diehl N.N., Wuu J., Miller T.M., Pastor P., Trojanowski J.Q., Grossman M., et al. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann. Neurol. 2017;82:139&#x2013;146. doi: 10.1002/ana.24980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Anderl-Straub S., Diehl-Schmid J., Semler E., Uttner I., von Arnim C.A.F., Barthel H., Danek A., Fassbender K., Fliessbach K., et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology. 2018;91:e1390&#x2013;e1401. doi: 10.1212/WNL.0000000000006318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006318</ArticleId><ArticleId IdType="pubmed">30209235</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.V., Irwin D.J., Blennow K., Zetterberg H., Lee E.B., Shaw L.M., Rascovsky K., Massimo L., McMillan C.T., Chen-Plotkin A., et al. Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurol. Clin. Pract. 2021;11:105&#x2013;116. doi: 10.1212/CPJ.0000000000000959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000959</ArticleId><ArticleId IdType="pmc">PMC8032415</ArticleId><ArticleId IdType="pubmed">33842063</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Turner M.R. Untangling neuroinflammation in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:1303&#x2013;1304. doi: 10.1136/jnnp-2019-320442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31296587</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhak A., Foschi M., Abu-Rumeileh S., Yue J.K., D&#x2019;Anna L., Huss A., Oeckl P., Ludolph A.C., Kuhle J., Petzold A., et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 2022;18:158&#x2013;172. doi: 10.1038/s41582-021-00616-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-021-00616-3</ArticleId><ArticleId IdType="pubmed">35115728</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P., Anderl-Straub S., Von Arnim C.A.F., Baldeiras I., Diehl-Schmid J., Grimmer T., Halbgebauer S., Kort A.M., Lima M., Marques T.M., et al. Serum GFAP differentiates Alzheimer&#x2019;s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J. Neurol. Neurosurg. Psychiatry. 2022;93:659&#x2013;667. doi: 10.1136/jnnp-2021-328547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328547</ArticleId><ArticleId IdType="pubmed">35477892</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 2013;368:117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 2013;368:107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A., Heywood W., Paterson R., Magdalinou N., Svensson J., Johansson P., Ohrfelt A., Blennow K., Hardy J., Schott J., et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer&#x2019;s disease. Mol. Neurodegener. 2016;11:3. doi: 10.1186/s13024-016-0071-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0071-x</ArticleId><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L., Deming Y., Del-Aguila J.L., Ghezzi L., Holtzman D.M., Fagan A.M., Fenoglio C., Galimberti D., Borroni B., Cruchaga C. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925&#x2013;933. doi: 10.1007/s00401-016-1533-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1533-5</ArticleId><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M., Morenas-Rodriguez E., Kleinberger G., Schlepckow K., Araque Caballero M.A., Franzmeier N., Capell A., Fellerer K., Nuscher B., Eren E., et al. Early increase of CSF sTREM2 in Alzheimer&#x2019;s disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology. Mol. Neurodegener. 2019;14:1. doi: 10.1186/s13024-018-0301-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0301-5</ArticleId><ArticleId IdType="pmc">PMC6327425</ArticleId><ArticleId IdType="pubmed">30630532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C., Gillardon F., Deuschle C., Hobert M.A., Jansen I.E., Metzger F.G., Heutink P., Gasser T., Maetzler W., Blauwendraat C., et al. Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia. Neurodegener Dis. 2017;17:83&#x2013;88. doi: 10.1159/000448896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000448896</ArticleId><ArticleId IdType="pubmed">27760429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K., Brouwers N., Maurer-Stroh S., van Es M.A., Van Damme P., van Vught P.W., van der Zee J., Serneels S., De Pooter T., Van den Broeck M., et al. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology. 2008;71:253&#x2013;259. doi: 10.1212/01.wnl.0000289191.54852.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000289191.54852.75</ArticleId><ArticleId IdType="pubmed">18184915</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., De Muynck L., Thu H.N., Weynants B., Vanacker P., Dhondt J., Sleegers K., Schelhaas H.J., Verbeek M., Vandenberghe R., et al. Microglial upregulation of progranulin as a marker of motor neuron degeneration. J. Neuropathol. Exp. Neurol. 2010;69:1191&#x2013;1200. doi: 10.1097/NEN.0b013e3181fc9aea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181fc9aea</ArticleId><ArticleId IdType="pubmed">21107132</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbgebauer S., Steinacker P., Hengge S., Oeckl P., Abu Rumeileh S., Anderl-Straub S., Lombardi J., Von Arnim C.A.F., Giese A., Ludolph A.C., et al. CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer&#x2019;s disease. J. Neurol. Neurosurg. Psychiatry. 2022;93:1059&#x2013;1065. doi: 10.1136/jnnp-2021-328646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328646</ArticleId><ArticleId IdType="pubmed">35995553</ArticleId></ArticleIdList></Reference><Reference><Citation>Serot J.M., Christmann D., Dubost T., Couturier M. Cerebrospinal fluid transthyretin: Aging and late onset Alzheimer&#x2019;s disease. J. Neurol. Neurosurg. Psychiatry. 1997;63:506&#x2013;508. doi: 10.1136/jnnp.63.4.506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.63.4.506</ArticleId><ArticleId IdType="pmc">PMC2169793</ArticleId><ArticleId IdType="pubmed">9343132</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulsen K., Bahl J.M., Tanassi J.T., Simonsen A.H., Heegaard N.H. Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. Methods. 2012;56:284&#x2013;292. doi: 10.1016/j.ymeth.2011.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2011.12.009</ArticleId><ArticleId IdType="pubmed">22286025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S., Williams E., Ganchev P., Gopalakrishnan V., Lacomis D., Urbinelli L., Newhall K., Cudkowicz M.E., Brown R.H., Jr., Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J. Neurochem. 2005;95:1461&#x2013;1471. doi: 10.1111/j.1471-4159.2005.03478.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03478.x</ArticleId><ArticleId IdType="pmc">PMC1540444</ArticleId><ArticleId IdType="pubmed">16313519</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Lehmensiek V., Mogel H., Pfeifle M., Dorst J., Hendrich C., Ludolph A.C., Tumani H. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS) Neurosci. Lett. 2010;468:23&#x2013;27. doi: 10.1016/j.neulet.2009.10.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2009.10.053</ArticleId><ArticleId IdType="pubmed">19853641</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory J.M., Whiten D.R., Brown R.A., Barros T.P., Kumita J.R., Yerbury J.J., Satapathy S., McDade K., Smith C., Luheshi L.M., et al. Clusterin protects neurons against intracellular proteotoxicity. Acta Neuropathol. Commun. 2017;5:81. doi: 10.1186/s40478-017-0481-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0481-1</ArticleId><ArticleId IdType="pmc">PMC5678579</ArticleId><ArticleId IdType="pubmed">29115989</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijnenburg Y.A., Janssen J.C., Schoonenboom N.S., Petzold A., Mulder C., Stigbrand T., Norgren N., Heijst H., Hack C.E., Scheltens P., et al. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer&#x2019;s disease and controls. Dement. Geriatr. Cogn. Disord. 2007;23:225&#x2013;230. doi: 10.1159/000099473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000099473</ArticleId><ArticleId IdType="pubmed">17290105</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonenboom N.S., Reesink F.E., Verwey N.A., Kester M.I., Teunissen C.E., van de Ven P.M., Pijnenburg Y.A., Blankenstein M.A., Rozemuller A.J., Scheltens P., et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78:47&#x2013;54. doi: 10.1212/WNL.0b013e31823ed0f0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31823ed0f0</ArticleId><ArticleId IdType="pubmed">22170879</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W.T., Watts K., Grossman M., Glass J., Lah J.J., Hales C., Shelnutt M., Van Deerlin V., Trojanowski J.Q., Levey A.I. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81:1945&#x2013;1952. doi: 10.1212/01.wnl.0000436625.63650.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000436625.63650.27</ArticleId><ArticleId IdType="pmc">PMC3843382</ArticleId><ArticleId IdType="pubmed">24174584</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E., Steinacker P., Lehnert S., Schneider A., Walther P., Thal D.R., Linsenmeier M., Ludolph A.C., Otto M. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Front. Degener. 2014;15:351&#x2013;356. doi: 10.3109/21678421.2014.905606.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.905606</ArticleId><ArticleId IdType="pubmed">24834468</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiperij H.B., Versleijen A.A., Beenes M., Verwey N.A., Benussi L., Paterlini A., Binetti G., Teunissen C.E., Raaphorst J., Schelhaas H.J., et al. Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. J. Alzheimers Dis. 2017;55:585&#x2013;595. doi: 10.3233/JAD-160386.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160386</ArticleId><ArticleId IdType="pubmed">27662293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan R.H., Shepherd C.E., Kril J.J., McCann H., McGeachie A., McGinley C., Affleck A., Halliday G.M. Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol. Commun. 2013;1:33. doi: 10.1186/2051-5960-1-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-1-33</ArticleId><ArticleId IdType="pmc">PMC4046675</ArticleId><ArticleId IdType="pubmed">24252630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T., Kojima Y., Ohmichi T., Tatebe H., Tsuji Y., Noto Y.I., Kitani-Morii F., Shinomoto M., Allsop D., Mizuno T., et al. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. Ann. Clin. Transl. Neurol. 2019;6:2489&#x2013;2502. doi: 10.1002/acn3.50943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50943</ArticleId><ArticleId IdType="pmc">PMC6917342</ArticleId><ArticleId IdType="pubmed">31742901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima Y., Kasai T., Noto Y.I., Ohmichi T., Tatebe H., Kitaoji T., Tsuji Y., Kitani-Morii F., Shinomoto M., Allsop D., et al. Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics. PLoS ONE. 2021;16:e0260323. doi: 10.1371/journal.pone.0260323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260323</ArticleId><ArticleId IdType="pmc">PMC8629269</ArticleId><ArticleId IdType="pubmed">34843548</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero D., La Salvia S., Colombo F., Zucca S., Pansarasa O., Diamanti L., Costa A., Lova L., Giannini M., Gagliardi S., et al. Leukocyte Derived Microvesicles as Disease Progression Biomarkers in Slow Progressing Amyotrophic Lateral Sclerosis Patients. Front. Neurosci. 2019;13:344. doi: 10.3389/fnins.2019.00344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00344</ArticleId><ArticleId IdType="pmc">PMC6476347</ArticleId><ArticleId IdType="pubmed">31037054</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>